Sygnis SA

Equities

SYG

PLMODE000019

Biotechnology & Medical Research

End-of-day quote Warsaw S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.7 ^PLN	+5.74%		-1.13%	-21.88%

Feb. 14	Sygnis SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Feb. 14	Sygnis SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

An unknown buyer acquired 14.92% stake in MODE S.A. from SETANTA Alternatywna Spólka Inwestycyjna Spólka Akcyjna.

June 17, 2018

An unknown buyer acquired 14.92% stake in MODE S.A. (WSE:MOE) from SETANTA Alternatywna Spólka Inwestycyjna Spólka Akcyjna (WSE:SET) on June 15, 2018.

An unknown buyer completed the acquisition of 14.92% stake in MODE S.A. (WSE:MOE) from SETANTA Alternatywna Spólka Inwestycyjna Spólka Akcyjna (WSE:SET) on June 15, 2018.

Latest news about Sygnis SA

Sygnis SA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
Sygnis SA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Sygnis SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Sygnis SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Sygnis SA Auditor Raises 'Going Concern' Doubt	23-03-19	CI
Sygnis SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Sygnis SA acquired majority stake in ZMorph sp. z o.o. from Warsaw Equity Group for PLN 3.64 Million.	22-07-28	CI
Sygnis SA Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Sygnis SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
Sygnis SA Auditor Raises 'Going Concern' Doubt	22-03-20	CI
MODE S.A. will Change its Name to Sygnis SA	22-01-28	CI
MODE S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
MODE S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-12	CI
Mode S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
An unknown buyer acquired 14.92% stake in MODE S.A. from SETANTA Alternatywna Spólka Inwestycyjna Spólka Akcyjna.	18-06-17	CI

Chart Sygnis SA

Duration

Period

More charts

Company Profile

Sygnis SA is a Poland-based company, which egages in Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SYGNIS SA	-21.88%	4.36M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research